The National Heart, Lung, and Blood Institute (NHLBI), under the federal Cardiovascular Diseases Research program (CFDA 93.837), awarded a $306,643 project grant to Mira Medical, LLC to develop a new extracorporeal membrane oxygenation (ECMO) pump designed to efficiently accommodate the low flow rates needed for pediatric and neonatal patients. The project aims to design, develop, and test a low-flow ECMO pump capable of operating at flow rates from 0.05 to 0.5 L/min, which is an order of...
This STTR Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $294,063 to Biomembretics, Inc. to develop and demonstrate a high-volume manufacturing technology for microfluidic oxygenators for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a bioinspired microfluidic oxygenator technology that can safely and effectively oxygenate blood, addressing limitations of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,924 to Convergent Engineering, Inc. to develop a prototype decision support system for personalized mechanical ventilation care. The system aims to simplify the use of esophageal pressure measurements to optimize ventilator settings and prevent complications for ventilated patients. The project has two key objectives: 1) Building a...
This Project Grant award, valued at $870,467, was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the development of Ension Inc.'s Bearingless Pediatric Cardiopulmonary Assist System (PCAS), which incorporates an innovative Bearingless Flux Reversal Motor (FRM) technology. This system is designed to address shortcomings of the current clinically available pediatric blood pump, the Abbott PediMag,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $163,760 to Tufts Medical Center to conduct research on how veno-arterial extracorporeal membrane oxygenation (VA-ECMO) affects ventricular-vascular coupling in the context of acute myocardial infarction (AMI). The research aims to determine how VA-ECMO alters afterload, identify strategies to mitigate increases in left...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop an accurate and continuous monitoring platform for classifying apnea of prematurity (AOP) in premature newborns. The $371,021 award to Makani Science Inc., a minority-owned small business, will fund a two-phase effort to create a multimodal AOP monitoring system utilizing machine learning. During the initial R61 phase, the team...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $423,921 to Advanced Medical Electronics Corp (A M E C) to develop an innovative, single-operator pneumothorax decompression device. The aim is to improve the safety and time efficiency of therapeutic decompression procedures to alleviate air pockets in the chest wall that threaten vital organ functionality, particularly for...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $117,750 to the Ann & Robert H. Lurie Children's Hospital of Chicago to develop and validate a remote patient monitoring system for children using home mechanical ventilation. The key objectives are to: 1) validate the use of wireless biosensors and a portable capnograph to continuously collect physiologic data, as an alternative to manual data collection by...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $1,160,157 Project Grant to Liberandum Technologies, Inc. to develop and test a novel bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in patients with acute respiratory distress syndrome (ARDS). The goal of this 1-year Phase I SBIR project is to create a ventilation system that can provide gentle...
PEDIATRIC ECMO OXYGENATOR WITH INTEGRATED MONITORING - ABSTRACT EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IS INCREASINGLY UTILIZED TO PROVIDE CARDIOPULMONARY SUPPORT IN PATIENTS DUE TO ITS VERSATILITY, IMMEDIATE BENEFIT, AND RELATIVELY LOW COST. HOWEVER, THERE CONTINUES TO BE SIGNIFICANT MORBIDITY AND MORTALITY RELATED TO HEMOSTATIC COMPLICATIONS, ESPECIALLY IN THE NEONATAL AND PEDIATRIC POPULATION. A FEW PEDIATRIC OXYGENATORS ARE USED IN ECMO; HOWEVER, ALL OF THESE DEVICES ONLY HAVE SHORT TERM APPROVAL AND ARE CURRENTLY USED OFF LABEL IN ECMO. IN ADDITION, A VARIETY OF MONITORS ARE NEEDED IN AN ECMO CIRCUIT, WHICH ADD TO THE COMPLEXITY OF THE WORKFLOW AND INTRODUCE ACCESS SITES THAT CAN DISRUPT THE BLOOD FLOW PATH. CURRENTLY, THERE IS NO SUCH OXYGENATOR APPROVED FOR LONG TERM USE IN PEDIATRICS. THE GOAL OF THIS PROJECT IS TO DEVELOP A PEDIATRIC ECMO OXYGENATOR WITH INTEGRATED SENSORS THAT IS OPTIMIZED FOR LONG TERM USE IN PEDIATRIC ECMO. IN PHASE I, THE MC3 PED-ECMO OXYGENATOR (PEDOXY) WAS DESIGNED SPECIFICALLY WITH AN OPTIMIZED FLOW PATH THAT MINIMIZES CLOTTING BY AVOIDING AREAS OF HIGH SHEAR AS WELL AS STAGNANT ZONES. A NON-HEPARIN COATING, BALANCE BIOSURFACE, HAS BEEN SELECTED TO PREVENT THROMBOSIS AND PRESERVE PLATELET FUNCTION. IN ADDITION, A SIMPLIFIED MONITORING SYSTEM WAS INTEGRATED INTO THE DISPOSABLE OXYGENATOR THAT WILL PROVIDE REAL-TIME DIAGNOSTICS, MINIMIZE BLOOD PATH DISRUPTIONS AND SIMPLIFY WORKFLOWS. THE MANUFACTURING PROCESSES FOR CREATING THE UNIQUE FLOW PATH WAS ADVANCED. PROTOTYPES OF THE PEDOXY WERE DEMONSTRATED TO MATCH COMPETITORS' GAS EXCHANGE WHILE SHOWING SUPERIOR CLOTTING PERFORMANCE IN VITRO. WITH PHASE II FUNDING, THE MC3 PEDOXY WILL REACH DESIGN FREEZE, VERIFICATION/VALIDATION TESTING WILL BE COMPLETED, AND THE DESIGN WILL BE TRANSFERRED TO IN-HOUSE MC3 MANUFACTURING. PILOT IN VIVO STUDIES WILL BE PERFORMED TO PREPARE FOR THE GLP STUDY THAT IS REQUIRED FOR REGULATORY SUBMISSIONS FOR THE ECMO PATHWAY IN THE US AND CE MARK IN ACCORDANCE WITH THE NEW EUROPEAN MEDICAL DEVICE REGULATION. WE HAVE ASSEMBLED A TEAM OF EXPERTS, CLINICIANS, MARKETERS, MANUFACTURERS AND ENGINEERS WHO ARE UNIQUELY QUALIFIED TO CARRY OUT THE PROPOSED WORK.